A phase 1/2 trial of TST003 in colorectal cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., active and no longer recruiting.
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05731271 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 111 participants enrolled, started 2023-02-08 and due to reach its primary completion in 2026-06. Interventions recorded: TST003.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.